BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Research Notes

JPMorgan: Record Earnings, a 99th-Percentile Price Tag, and One Open Question

Moe Alsumidaie by Moe Alsumidaie
August 25, 2026
in Research Notes
0
74
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

The heart of it

The filed numbers show a bank earning more than it ever has, with net income of $57 billion in 2025 and trading revenue surging by more than a third in the most recent quarter. The stock is priced at a multiple the bank itself has reached only at the very top of its own decade-long range. The math says the business is genuinely stronger; the mood, meaning what the market is currently paying per dollar of profit, says that strength is already fully priced and then some. Those two readings can coexist for a while. They rarely coexist forever.

A bank that grew up in a crisis, priced for a golden age

JPMorgan spent the decade after 2008 building what Jamie Dimon calls a “fortress balance sheet,” accumulating capital while rivals shrank. When the Federal Reserve began raising rates aggressively in June 2022, JPMorgan was positioned to collect: higher rates mean banks earn more on every loan and every dollar parked in Treasuries. Over roughly four years, revenue climbed by an amount equivalent to adding an entire mid-sized bank’s annual income on top of what JPMorgan already earned.

Now rates have settled. The Fed held its target steady through both its June and July 2026 meetings, and market pricing as of mid-August implies rates stay roughly here through year-end. The easy tailwind, the one that let JPMorgan raise its own guidance almost every quarter from 2022 onward, has stopped blowing harder. What’s left is the question of whether the underlying business compounds on its own.

What the Q2 filing actually shows

The 10-Q for the quarter ended June 30, 2026 contains two numbers that pull in opposite directions. Net interest income, the spread the bank earns between what it charges borrowers and what it pays depositors, rose to $25.6 billion for the quarter, up from $23.3 billion a year earlier. That’s the compounding story: deposits grew at a healthy clip year-over-year and the bank held its spread even as the rate cycle plateaued.

BullScope TerminalYou just read JPM’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →

Trading revenue hit its highest level in recent memory, driven by an equity markets surge that nearly doubled year-over-year, according to Seeking Alpha’s earnings coverage. Investment banking fees rose sharply and reached their highest level since 2021. These are genuinely strong numbers. They are also, by definition, hard to repeat: a quarter where equities revenue nearly doubles sets a high bar for the next comparison.

Credit quality, the measure of how many borrowers are failing to repay, improved modestly. The money set aside in case loans go bad fell meaningfully from a year earlier. The card charge-off rate, the share of credit-card balances written off as uncollectable, came in at roughly 3.2%, and Motley Fool’s coverage of Dimon’s July earnings call noted management guided the full-year rate to that same level, better than previously expected. A household analogy: if a lender had budgeted for roughly three and a half bad loans in every hundred, it’s now budgeting for three and a fifth. The improvement is real, if not dramatic.

The price the market is paying

Here is where the math and the mood diverge most sharply. JPMorgan’s price-to-earnings multiple, simply the price tag per dollar of annual profit, sits at 16.4 times by our data, against a decade median of 12.1 times. The current reading lands at the 99th percentile of its own history, meaning the stock has traded this expensively or more expensively less than 1% of the time over the past ten years.

That premium is not irrational on its face. The business genuinely earns more per dollar of equity than it used to, as the 10-K filed in February 2026 makes clear: a return on tangible common equity of 20% for 2025 is a measure of how efficiently the bank converts shareholder capital into profit, and it is genuinely high by historical standards. A more profitable business deserves a higher multiple. The open question is how much higher, and whether the current price already assumes every good thing goes right.

What could change the story

Two risks in the current filings are worth naming plainly. First, the SEC issued a subpoena to JPMorgan in late August 2026, as reported by CNBC, related to loans made to an AI-focused hedge fund that lost the majority of its value in a single month. The Justice Department is also examining the bank’s late-2025 decision to end banking services for a prediction market. Neither investigation has produced charges, and the data cannot tell us where either leads. We flag them because they are live regulatory risks named in public reporting, not because the outcome is knowable.

Second, Dimon himself told Motley Fool’s earnings coverage that the economy feels “close to as good as it gets,” while also calling out low credit spreads and market exuberance as potential risks. A CEO describing peak conditions is not predicting a downturn, but it is worth noting that the bank’s own leader is not arguing the good times have further to run.

Reading the numbers

  • Net interest income, Q2 2026: $25.6 billion. This is the spread the bank earns between loan rates and deposit costs. Up from $23.3 billion a year earlier. Think of a household that borrows at 7% and lends its savings at 2%: the gap is the income. A wider or larger gap means more earnings without selling anything new.
  • Full-year 2025 net income: $57 billion. What the bank kept after all costs and taxes. To anchor the size: $57 billion is more than the entire annual revenue of most Fortune 500 companies. It is profit, not sales.
  • Trading revenue, Q2 2026: $12.1 billion, up 35% year-over-year. Markets revenue swings with activity levels. An 86% surge in equity trading in a single quarter is exceptional. A saver watching this number should treat it the way a homeowner treats a bonus: real money, but not the salary to budget from.
  • P/E multiple: 16.4 times, 99th percentile of JPMorgan’s own decade. A multiple is the price tag per dollar of annual profit. At 12 times (the decade median), a dollar of profit costs $12. Today it costs $16.40. That extra $4.40 per dollar of profit is the market’s bet that future profits will be meaningfully higher than today’s. If earnings land at the filed-trend pace and the multiple reverts toward its decade median, the math would put fair value considerably below today’s price. If the bank sustains its elevated returns and the premium holds, the current price is defensible. The condition matters as much as the number.

Sources

  • JPMorgan 10-Q, quarter ended June 30, 2026 (SEC EDGAR)
  • JPMorgan 10-K, fiscal year ended December 31, 2025 (SEC EDGAR)
  • BusinessWire: JPMorganChase Files Form 10-K for Fiscal Year 2025
  • Seeking Alpha: JPMorgan Q2 2026 earnings coverage
  • Motley Fool: Dimon Q2 2026 earnings call coverage
  • Federal Reserve: June 2022 rate decision
  • J.P. Morgan Asset Management: FOMC Statement, June 2026
  • J.P. Morgan Asset Management: FOMC Statement, July 2026
  • CNBC: Dimon interview transcript, August 2026
BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.
BullScope TerminalYou just read JPM’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie

Moe Alsumidaie

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.

Recommended For You

Arcutis: One Drug, Shrinking Losses, and a Label That Keeps Growing

by Moe Alsumidaie
October 23, 2026
0

For most of its life, Arcutis Biotherapeutics was a company with a single compelling bet: that a molecule called roflumilast, already proven in lung disease, could be reformulated...

Read moreDetails

One Drug, Nearly a Billion Dollars, and a Pipeline That Just Blinked

by Moe Alsumidaie
October 21, 2026
0

The short version Krystal Biotech built a profitable, cash-rich business on a single gene therapy approved just three years ago. The filed numbers show margins expanding sharply and...

Read moreDetails

Ardelyx: The Revenue Is Real, the Guidance Cut Is Realer

by Moe Alsumidaie
October 20, 2026
0

Three years ago, Ardelyx was burning through cash with almost nothing to show at the pharmacy counter. Then IBSRELA, its drug for irritable bowel syndrome with constipation, started...

Read moreDetails

Innoviva: The Royalties Are Shrinking. The Specialty Business Is Growing. Both Things Are True at Once.

by Moe Alsumidaie
October 20, 2026
0

Innoviva spent most of its life as a toll booth on two GSK inhalers. Every time a patient filled a BREO or ANORO prescription, Innoviva collected a royalty...

Read moreDetails

One Drug Is Carrying the Weight. Two Acquisitions Just Added More.

by Moe Alsumidaie
October 19, 2026
0

Three years ago, Tarsus Pharmaceuticals was shrinking. Revenue had fallen by more than half in 2022, then fell again in 2023, and the company was burning through cash...

Read moreDetails
Next Post

Evidence Sheet: JPMorgan Chase & (JPM)

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

Viatris: The Stock Has Run 72% in a Year. The Filed Numbers Tell a More Complicated Story.

October 9, 2026

USANA: The Cash Is Real, the Loss Is Not, and the Customer Count Is the Story

September 18, 2026

Evidence Sheet: American Express (AXP)

October 16, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.